Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
By A. Wolff, M. Elizabeth, H. Hammond, K. Allison, Brittany E. Harvey, P. Mangu, J. Bartlett, M. Bilous, Ian O. Ellis, P. Fitzgibbons and 8 more. Journal of Clinical Oncology, 2018
1,382 citations recorded by the source corpus.
Purpose To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. Methods Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations. Recommendations Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in > 10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not "must") be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended work-up for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 ( HER2/chromosome enumeration probe 17 [CEP17] ratio ≥ 2.0; average HER2 copy number < 4.0 signals per cell), ISH group 3 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 6.0 signals per cell), and ISH group 4 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 4.0 and < 6.0 signals per cell). The diagnostic approach includes more rigorous interpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to arrive at the most accurate HER2 status designation (positive or negative) based on combined interpretation of the ISH and IHC assays. The Expert Panel recommends that laboratories using single-probe ISH assays include concomitant IHC review as part of the interpretation of all single-probe ISH assay results. Find additional information at www.asco.org/breast-cancer-guidelines .
Subfields: Genetics, Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/5f4e07bfa10edabdd16c614493dd28222472247f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Oncology
Citations in the corpus
- Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020, positive): “Log transformation is required for parametric statistical testing. aASCO/CAP ¼ American Society of Clinical Oncology and the College of American Pathologists; ER ¼ estrogen receptor; IHC ¼ immunohistochemistry; NEQAS ¼ National External Quality Assessment Scheme.”
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020, neutral): “Tumours with staining of ER <1% and progesterone receptor (PgR)<1%andwithHER2-negative results by IHC and/ or in situ hybridisation are defined as TNBC.(91) Patients with a low (1%-10%) expression of hormone receptors and HER2negative account for 2%-3% of breast cancers.”